DAXOR CORP - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2007. Daxor Corporation operates as a medical device manufacturer focusing on the Blood Volume Analyzer (BVA-100) and related diagnostic kits, alongside a subsidiary providing cryobanking services (blood and semen storage). A significant portion of the company's financial profile is driven by a large investment portfolio, which management utilizes to offset operating losses.
Key Financial Metrics
Revenue and Profitability (Six Months Ended June 30, 2007):
- Total Revenues: $1,051,200 (up 43.7% from $731,468 in 2006).
- Gross Profit: $754,640 (Gross Margin: 71.8%).
- Operating Loss: $(2,440,128) (improved from $(2,797,725) in 2006).
- Net Income: $5,399,909 (driven primarily by investment gains).
- Diluted EPS: $1.17 (compared to $0.02 in 2006).
Balance Sheet and Liquidity (as of June 30, 2007):
- Total Assets: $80,386,989.
- Cash and Cash Equivalents: $37,697 (down significantly from $2.84M at year-end 2006).
- Available-for-Sale Securities: $70,013,081 (Fair Market Value).
- Total Current Liabilities: $27,635,741 (includes $16.2M deferred tax liability).
- Stockholders' Equity: $52,301,644.
Cash Flow (Six Months Ended June 30, 2007):
- Net Cash Used in Operating Activities: $(1,647,510).
- Net Cash Provided by Investing Activities: $2,461,423.
- Net Cash Used in Financing Activities: $(3,615,143).
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 40.1% in Q2 and 43.7% for the six-month period, primarily due to the sale of five Blood Volume Analyzers in the first half of 2007 (vs. one in 2006) and a 5% price increase on Volumex kits effective February 2007.
- Investment Income Surge: Net investment income for the six months ended June 30, 2007, was $7,978,463, compared to $3,073,523 in the prior year. This was driven by realized gains on securities sales ($3.44M) and mark-to-market gains on short positions ($3.33M).
- Operating Expenses: Total operating expenses remained relatively flat year-over-year for the six-month period ($3.19M vs $3.20M), despite increased R&D spending, due to cost allocations between segments and reduced fees for employment agencies and contractors.
- Asset Acquisition: The company purchased land and buildings in Oak Ridge, Tennessee, for $784,064 in January 2007, financed by a new $500,000 mortgage.
Outlook, Risks, and Contingencies
Management Commentary: Management notes that the investment portfolio has been critical to offsetting continuing operating losses over the past decade. The company is expanding R&D for renal function testing (GFR) and a needle-less delivery device ("Max-200"). They anticipate hiring regional managers to expand sales but noted that recent attempts to raise additional capital were disadvantageous to shareholders.
Risks and Contingencies:
- SEC Investigation: The SEC has recommended action against the company and its CEO, Dr. Joseph Feldschuh, for potential violations of the Investment Company Act of 1940. The company is cooperating with information requests but cannot predict the outcome or potential penalties.
- Customer Concentration: Five hospital customers accounted for 38.5% of total consolidated sales in the first six months of 2007. The loss of any single customer could have an adverse effect.
- Single Source Supplier: The company relies on a single FDA-approved manufacturer to fill Volumex syringes. Discontinuation by this supplier would materially impact the business.
- Investment Risk: While the portfolio has maintained value above cost for 90 consecutive quarters, it is heavily concentrated in electric utilities. The company utilizes short sales and options, which are marked to market and introduce volatility to earnings.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing SEC investigation regarding the Investment Company Act.
- Assess the sustainability of investment income, noting that net income is currently driven by portfolio gains rather than core operations.
- Review the concentration risk associated with the top five hospital customers representing 38.5% of sales.
- Confirm the operational timeline for the new Oak Ridge, Tennessee facility and its impact on future capacity.
- Monitor the dependency on the single supplier for Volumex syringes and any potential supply chain disruptions.